Brii Biosciences Limited
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Zhi Hong
- Full Time Employees
- 75
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Building 7 Beijing BE People's Republic of China 100192
- IPO Date
- Jan 21, 2022
- Website
- briibio.com
- Similar Companies
- Business
- Brii Biosciences Limited (BRIBF) is a biotechnology company focused on developing innovative therapies for infectious diseases, including chronic hepatitis B virus (HBV), COVID-19, HIV and other multi-drug resistant infections, and central nervous system disorders. The company offers a pipeline of product candidates such as the HBV therapeutic vaccine BRII-179, a recombinant protein-based HBV immunotherapeutic; elebsiran (BRII-835), an HBV-targeting siRNA; BRII-877 (tobevibart), an HBV neutralizing antibody; soralimixin (BRII-693), an anti-infective agent; lufotrelvir, a SARS-CoV-2 3CLpro inhibitor in Phase 3 for COVID-19; amubarvimab and romlusevimab, approved monoclonal antibodies targeting SARS-CoV-2 S protein for COVID-19; and early-stage assets including small molecule drugs, prophylactic vaccines and genetically engineered subunit vaccines. Founded in 2018 by Zhi Hong and headquartered in Durham, North Carolina, with additional operations in the San Francisco Bay Area, Beijing and Shanghai, Brii Biosciences conducts research, development and clinical trials primarily targeting patients in China, the United States and global markets with high unmet needs in public health challenges. Recent developments include the July 2025 strategic out-licensing of soralimixin (BRII-693) to Joincare Pharmaceutical Group Industry Co., Ltd. for development and commercialization in Greater China, leveraging Joincare's anti-infective expertise; full enrollment in December 2024 of the Phase 2b ENRICH study evaluating sequential BRII-179, elebsiran and pegylated interferon alpha for HBV functional cure; acquisition in late 2024 of full intellectual property rights to BRII-179 from VBI Vaccines for US$18 million, securing manufacturing control and eliminating future royalties; advancement of Phase 2b HBV studies ENSURE, ENRICH and ENHANCE showing encouraging functional cure data; expansion of early-stage discovery programs; and a December 2024 HK$60 million share buyback program representing 10% of outstanding shares.
Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV
Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026
Brii Biosciences Limited (BRIBF) Q4 2025 Earnings Call Transcript
Brii Biosciences Provides Corporate Updates and Reports Full Year 2025 Financial Results
Brii Biosciences Announces Publication of Phase 2 ENSURE Study Results in Nature Medicine
Brii Biosciences Provides Corporate Updates and Reports 2025 Interim Financial Results
Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China
Brii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179's Role in Advancing Higher HBsAg Loss
Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179's Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification
Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results
Brii Bio Announces Signing of Asset Purchase Agreements Acquiring BRII-179 IP Rights and Completed Patient Enrollment for ENRICH Study
Brii Bio Delivers First Head-to-Head Comparison of siRNA (Elebsiran) and PEG-IFNα Combination versus PEG-IFNα Alone at AASLD's The Liver Meeting® 2024, Demonstrating Higher Loss of HBV Surface Antigen by Combining with siRNA
Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer
Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023
Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results